CN110420223A - 一种含有骨髓间质干细胞的注射剂 - Google Patents
一种含有骨髓间质干细胞的注射剂 Download PDFInfo
- Publication number
- CN110420223A CN110420223A CN201910830407.XA CN201910830407A CN110420223A CN 110420223 A CN110420223 A CN 110420223A CN 201910830407 A CN201910830407 A CN 201910830407A CN 110420223 A CN110420223 A CN 110420223A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- bone marrow
- interstital stem
- marrow interstital
- lentinan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 47
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 41
- 238000002347 injection Methods 0.000 title claims abstract description 21
- 239000007924 injection Substances 0.000 title claims abstract description 21
- 241001061264 Astragalus Species 0.000 claims abstract description 29
- 229920001491 Lentinan Polymers 0.000 claims abstract description 29
- 235000006533 astragalus Nutrition 0.000 claims abstract description 29
- 229940115286 lentinan Drugs 0.000 claims abstract description 29
- 210000004233 talus Anatomy 0.000 claims abstract description 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 27
- 239000005017 polysaccharide Substances 0.000 claims abstract description 27
- -1 polysaccharide selenide Chemical class 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 24
- 239000004471 Glycine Substances 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 12
- 239000008103 glucose Substances 0.000 claims abstract description 12
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 16
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 15
- 239000001110 calcium chloride Substances 0.000 claims description 15
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000287 crude extract Substances 0.000 claims description 10
- 230000001079 digestive effect Effects 0.000 claims description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- 102000029816 Collagenase Human genes 0.000 claims description 5
- 108060005980 Collagenase Proteins 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 108010019160 Pancreatin Proteins 0.000 claims description 5
- 229960002424 collagenase Drugs 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 5
- 229940055695 pancreatin Drugs 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 2
- 230000036737 immune function Effects 0.000 abstract description 2
- 230000003076 paracrine Effects 0.000 abstract description 2
- 239000011734 sodium Substances 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- 239000005556 hormone Substances 0.000 description 9
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000006472 autoimmune response Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000003694 hair properties Effects 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 102100035488 Nectin-2 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000004995 autoimmune glomerulonephritis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- AJGPQPPJQDDCDA-UHFFFAOYSA-N azanium;hydron;oxalate Chemical compound N.OC(=O)C(O)=O AJGPQPPJQDDCDA-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 210000002391 femur head Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种含有骨髓间质干细胞的注射剂，本发明的一种含有骨髓间质干细胞的注射剂主要由血清、林格氏液、葡萄糖、甘氨酸、硒化黄芪多糖、香菇多糖和骨髓间质干细胞混合而成，无毒副作用，安全性好，该注射剂由于有林格氏液的存在补充机体所需要的钠钾元素，甘氨酸可以清除机体内自由基，促进干细胞分泌因子的旁分泌作用，硒化黄芪多糖和香菇多糖可以延长干细胞分泌因子的持续作用时间，同时增强机体非特异性免疫功能。
Description
技术领域
本发明涉及干细胞技术领域，具体涉及一种含有骨髓间质干细胞的注射剂。
背景技术
1.骨髓间质干细胞功能
骨髓中包含两种完全不同的干细胞：造血干细胞和间质干细胞（mesenchymal stemcells，MSCs），前者维持造血, 而后者则构成了骨髓造血的微环境。这两种独立而且完全不同的干细胞不仅共存而且在功能上互相协作, 共同完成成人体内血液系统的再造。除骨髓外，其他组织也存在少量MSCs，但成人中骨髓中含量最多，约占其有核细胞0.001～0.01%，因此骨髓是较为适合的MSCs来源。
1970年Friedenstein通过成纤维细胞集落形成单位试验在体外证明了MSCs的存在；经过长期的研究, 人们对其功能已有了比较深入的了解。骨髓MSCs为多潜能的成体基质细胞，能分化为多种间质起源的组织，如成骨、软骨和脂肪细胞；在特殊环境下，还能横向分化为肌细胞、神经细胞、血管内皮细胞、肝胰细胞等多种其他组织细胞。MSCs对多种损伤组织具有替代修复作用，植入体内后可在多种造血以外的组织如肺、骨、软骨和皮肤等处定位和分布。
除了分化作用外，骨髓MSCs还具有较强的免疫调控能力，对T、B、树突状细胞和NK细胞均有调节性抑制作用。研究表明，MSCs可抑制T细胞增殖，引起T细胞分化停滞，并可抑制T细胞活化，下调相应肽段对幼稚性（naive）及记忆性抗原特异T细胞效应，诱导T细胞失能(anergy) ；此外MSCs还可诱导产生调节性T细胞来进行调控。MSCs可抑制B细胞增殖（B细胞/MSCs为1:1时作用最强，而达1:5或1:10时作用消失），抑制B细胞分化并影响B细胞趋化（与MSCs共培养后B细胞表达趋化因子CXCR4、CXCR5和CXCR7受体减少，从而出现趋化能力缺陷）。对于树突状细胞，MSCs可抑制其增殖及分化成熟，可阻止单核细胞和骨髓前体细胞分化为树突状细胞，抑制CD1a、CD40、CD80、CD86及HLA-DR上调，使细胞维持未成熟状态；MSCs还可改变其细胞因子分泌能力，从而影响树突状细胞功能。MSCs同样能够抑制NK细胞的增殖，其表面存在多种成分可影响NK细胞活化（包括NKG2D配体如MICA、ULBPs和DNAM-1配体如PVR、nectin-2）。
2.间质干细胞应用现状
MSCs可在造血干细胞niche中分泌细胞因子起支持作用，并且降低外周血单个核细胞同种免疫刺激活性，从而促进造血干细胞移植后造血系统重建。2000年，首项临床试验显示，28例女性乳腺癌患者在接受自体造血干细胞移植时给予MSCs单次输注，其造血恢复加快且无副反应。2005年另一项多中心研究也显示46例患者同时行异基因造血干细胞和MSCs治疗后多数造血恢复加快，未发现副作用。
2004年，Le Blanc报道首个MSCs治疗移植物抗宿主病(GVHD)病例，患儿为淋巴细胞白血病患者，MSCs由其母亲提供，于造血干细胞移植70天和170天时分别输注1次，患儿症状改善，胆红素水平下降。2008年，Le Blanc报道了MSCs治疗重度难治性GVHD II期临床研究结果，共治疗55例患者，结果30例患者完全缓解，另9例部分缓解。目前III期研究正在进行中。
MSCs可同时修复心肌和血管组织、具有免疫调节活性，并且具有易培养扩增满足移植需要的特点，这使其在心血管疾病治疗中存在理论价值，目前已应用于心肌梗塞、心肌缺血、心功能衰竭的治疗。经心肌直接注入是最常用的治疗方式，初步研究显示可改善心脏射血分数，提高患者生存率，但其疗效和安全性尚有待对照研究加以证实。
MSCs在神经系统疾病（如多发性硬化、肌萎缩侧索硬化）、成骨不全、皮肤创伤也有一些初步应用。由于MSCs的靶向性，在动物研究中已有用于肿瘤治疗的报道。
3. 自身免疫性疾病常规治疗
自身免疫性疾病(autoimlnune disease)是指以自身免疫应答反应导致组织器官损伤和相应功能障碍为主要发病机制的一类疾病。是临床上常见的一大类疾病，目前已被公认的自身免疫性疾病至少有30多种。根据自身免疫反应对组织器官造成损伤的范围，通常将自身免疫病分器官特异与非器官特性两大类。
临床上常见的自身免疫性疾病包括：结缔组织疾病：类风湿关节炎(RA)、幼年特发性关节炎(JIA)、系统性红斑狼疮(SLE)、干燥综合征(SS)、多肌炎/皮肌炎(PM/DM)、硬皮病(SSC)、系统性血管炎；神经肌肉疾病：多发性硬化症(MS)、重症肌无力(MG)、脱髓鞘疾病；内分泌性疾病：原发性贤上腺皮质萎缩、慢性甲状腺炎、青少年型糖尿病；消化系统疾病：慢性非特异性溃疡性结肠炎(Crohn病)、慢性活动性肝炎、恶性贫血与萎缩性胃炎；泌尿系统疾病：自身免疫性肾小球肾炎、肺肾出血性综合征；血液系统疾病：自身免疫性溶血性贫血、原发性血小板减少性紫癜 (ITP)、特发性白细胞减少症。
自身免疫性疾病的常规治疗方法有：
（1）肾上腺皮质激素：是多数自身免疫性疾病最常用的治疗药物，具有较快抑制免疫反应和较强的抗炎作用。近年采用的激素冲击疗法提高了危重症的缓解率，但是激素也有不少副作用，长期应用可以抑制下丘脑-垂体-肾上腺系统，垂体前叶分泌促肾上腺皮质激素的量明显减少，使肾上腺皮质素分泌减少，皮质腺出现萎缩，从而患者需要长期服用激素维持治疗，并且他们的应激能力减弱，容易出现感冒及各种感染，在受到外伤、冷风刺激、精神刺激、手术治疗其它疾病等应激状态时，由于体内激素的分泌不足，一方面可能诱发自身免疫性疾病发生或加重，另一方面会出现疲乏无力，食欲减退，低血糖反应，肌肉关节疼痛等肾上腺皮质分泌激素不足的症状。此外，激素还可导致肥胖、多毛、高血压、青光眼、糖尿病、消化道溃疡、出血、精神症状、骨质疏松、股骨头坏死等。
（2）免疫抑制剂：自身免疫反应对多数自身免疫性疾病的发生发展有密切关系，除激素外，临床工作中往往还需应用1－数种免疫抑制剂以控制患者病情发展。常用的免疫抑制剂有环磷酰胺、硫唑嘌呤、甲氨喋呤、霉酚酸酯等，这些药物的主要副作用有胃肠道反应、血液系统损害、泌尿系统反应、影响生育、脱发、增加肿瘤发生率等。大剂量人体免疫球蛋白静脉注射通过抗体封闭作用治疗激素和免疫抑制剂不能控制的难治性患者，国内外均有成功经验, 但此法对不同的病人疗效差异很大，也有一定的毒副作用，价格昂贵，应用受限。
（3）造血干细胞移植：尽管给予了激素和免疫抑制剂治疗，仍有不少病人病情得不到控制或不能耐受常规治疗带来的严重不良反应，这促使临床工作者不断探索新的治疗方法。造血干细胞移植（HSCT）是近十余年来发展起来的一项治疗手段，在治疗自身免疫性疾病时主要采用了自体HSCT方式，其治疗原理有两方面，一是在预处理时，通过大剂量化疗或全身照射摧毁患者的异常免疫系统，对自身免疫性疾病起缓解作用；二是移植的自体外周血干细胞以重建正常的免疫系统，在免疫重建中阻断自身抗体的产生或诱导对自身抗原的免疫耐受。根据最新统计，目前全世界有近1000例难治性自身免疫性疾病患者接受了HSCT，其中包括SSc 190例，SLE 86例，PM/DM 14例，RA 86例，MS 368例，克罗恩病21例。由于自体免疫疾病自体HSCT后仍有部分患者病情不能控制，部分病例在术后复发，加之移植治疗风险较高，相关死亡率约为7％，高于非自身免疫性疾病（3％），制约了该技术的广泛应用。移植相关死亡率与具体病种相关，从高到低依次为SSc、SLE、MS和RA；病例选择、支持治疗、预处理方案、是否去移植物中的淋巴细胞等也影响患者的存活率。
发明内容
为了解决上述问题，本发明提供了一种含有骨髓间质干细胞的注射剂，所述的注射剂可以有效的对系统性红斑狼疮、系统性硬化症、混合性结缔组织病、类风湿关节炎、多发性肌炎/皮肌炎、自身免疫性溶血性贫血、炎性肠病、白塞病、原发性胆汁性肝硬化等在内的一大类疾病有良好的治愈性。
本发明的目的在于提供一种含有骨髓间质干细胞的注射剂，其技术点在于：所述的含有骨髓间质干细胞的注射剂主要由血清、林格氏液、葡萄糖、甘氨酸、硒化黄芪多糖、香菇多糖和骨髓间质干细胞混合而成。
在本发明的有的实施例中，每1L所述血清中含有以下组分：
林格氏液 30~50mL
葡萄糖 6~10g
甘氨酸 5~10g
硒化黄芪多糖 2~5g
香菇多糖 3~6g
骨髓间质干细胞 5~9g。
在本发明的有的实施例中，所述的林格氏液为含有氯化钠、氯化钾和氯化钙的混合液，每100mL的所述林格氏液含有氯化钠850mg、氯化钠30mg、氯化钙33mg。
在本发明的有的实施例中，所述的硒化黄芪多糖的制备方法为：取5~6kg的II型黄芪多糖加入到50~60mL的脱水吡啶中，用磁力搅拌器搅拌，搅拌10~15min，然后分三次滴入含硒试剂-SeOCl2，每次滴入1~3L的SeOCl2后，充分搅拌，在常温下反应1h，分离除杂后得到所述的硒化黄芪多糖。
在本发明的有的实施例中，所述的含硒试剂-SeOCl2中含硒5~6wt％。
在本发明的有的实施例中，所述的香菇多糖的制备方法为：将香菇依次进行干燥、粉碎、浸泡、水提得到香菇多糖粗提物，然后将香菇多糖粗提物依次用氯苯、氯化钙、草酸铵、胰蛋白酶、Sevage试剂进行除蛋白，然后醇沉，最后采用丙酮进行分级沉淀，得到所述香菇多糖。
在本发明的有的实施例中，所述的骨髓间质干细胞的制备方法为：将骨髓去除残留血液，剪碎，用胶原酶消化，然后再加入胰酶消化，消化液用筛网过滤，去除未消化组织，将过滤后的消化液用磷酸缓冲液稀释，离心，获得细胞，将细胞接种于培养基内进行培养，得到大量骨髓间充质干细胞。
与现有技术相比，本发明的有益效果：
本发明的一种含有骨髓间质干细胞的注射剂主要由血清、林格氏液、葡萄糖、甘氨酸、硒化黄芪多糖、香菇多糖和骨髓间质干细胞混合而成，无毒副作用，安全性好，该注射剂由于有林格氏液的存在补充机体所需要的钠钾元素，甘氨酸可以清除机体内自由基，促进干细胞分泌因子的旁分泌作用，硒化黄芪多糖和香菇多糖可以延长干细胞分泌因子的持续作用时间，同时增强机体非特异性免疫功能。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，以使本领域的技术人员能够更好的理解本发明的优点和特征，从而对本发明的保护范围做出更为清楚的界定。本发明所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例，基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动的前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
本发明的一种含有骨髓间质干细胞的注射剂主要由血清、林格氏液、葡萄糖、甘氨酸、硒化黄芪多糖、香菇多糖和骨髓间质干细胞混合而成。
其中，每1L血清中含有以下组分：
林格氏液 40mL
葡萄糖 8g
甘氨酸 7.5g
硒化黄芪多糖 3.5g
香菇多糖 4.5g
骨髓间质干细胞 7g。
其中，林格氏液为含有氯化钠、氯化钾和氯化钙的混合液，每100mL的所述林格氏液含有氯化钠850mg、氯化钠30mg、氯化钙33mg。
其中，硒化黄芪多糖的制备方法为：取5.5kg的II型黄芪多糖加入到55mL的脱水吡啶中，用磁力搅拌器搅拌，搅拌12.5min，然后分三次滴入含硒试剂-SeOCl2，每次滴入2L的SeOCl2后，充分搅拌，在常温下反应1h，分离除杂后得到所述的硒化黄芪多糖。
其中，含硒试剂-SeOCl2中含硒5.5wt％。
其中，香菇多糖的制备方法为：将香菇依次进行干燥、粉碎、浸泡、水提得到香菇多糖粗提物，然后将香菇多糖粗提物依次用氯苯、氯化钙、草酸铵、胰蛋白酶、Sevage试剂进行除蛋白，然后醇沉，最后采用丙酮进行分级沉淀，得到所述香菇多糖。
其中，骨髓间质干细胞的制备方法为：将骨髓去除残留血液，剪碎，用胶原酶消化，然后再加入胰酶消化，消化液用筛网过滤，去除未消化组织，将过滤后的消化液用磷酸缓冲液稀释，离心，获得细胞，将细胞接种于培养基内进行培养，得到大量骨髓间充质干细胞。
实施例2
本发明的一种含有骨髓间质干细胞的注射剂主要由血清、林格氏液、葡萄糖、甘氨酸、硒化黄芪多糖、香菇多糖和骨髓间质干细胞混合而成。
其中，每1L血清中含有以下组分：
林格氏液 30mL
葡萄糖 6g
甘氨酸 5g
硒化黄芪多糖 2g
香菇多糖 3g
骨髓间质干细胞 5g。
其中，林格氏液为含有氯化钠、氯化钾和氯化钙的混合液，每100mL的所述林格氏液含有氯化钠850mg、氯化钠30mg、氯化钙33mg。
其中，硒化黄芪多糖的制备方法为：取5kg的II型黄芪多糖加入到50mL的脱水吡啶中，用磁力搅拌器搅拌，搅拌10min，然后分三次滴入含硒试剂-SeOCl2，每次滴入1L的SeOCl2后，充分搅拌，在常温下反应1h，分离除杂后得到所述的硒化黄芪多糖。
其中，含硒试剂-SeOCl2中含硒5wt％。
其中，香菇多糖的制备方法为：将香菇依次进行干燥、粉碎、浸泡、水提得到香菇多糖粗提物，然后将香菇多糖粗提物依次用氯苯、氯化钙、草酸铵、胰蛋白酶、Sevage试剂进行除蛋白，然后醇沉，最后采用丙酮进行分级沉淀，得到所述香菇多糖。
其中，骨髓间质干细胞的制备方法为：将骨髓去除残留血液，剪碎，用胶原酶消化，然后再加入胰酶消化，消化液用筛网过滤，去除未消化组织，将过滤后的消化液用磷酸缓冲液稀释，离心，获得细胞，将细胞接种于培养基内进行培养，得到大量骨髓间充质干细胞。
实施例3
本发明的一种含有骨髓间质干细胞的注射剂主要由血清、林格氏液、葡萄糖、甘氨酸、硒化黄芪多糖、香菇多糖和骨髓间质干细胞混合而成。
其中，每1L血清中含有以下组分：
林格氏液 50mL
葡萄糖 10g
甘氨酸 10g
硒化黄芪多糖 5g
香菇多糖 6g
骨髓间质干细胞 9g。
其中，林格氏液为含有氯化钠、氯化钾和氯化钙的混合液，每100mL的所述林格氏液含有氯化钠850mg、氯化钠30mg、氯化钙33mg。
其中，硒化黄芪多糖的制备方法为：取6kg的II型黄芪多糖加入到60mL的脱水吡啶中，用磁力搅拌器搅拌，搅拌15min，然后分三次滴入含硒试剂-SeOCl2，每次滴入3L的SeOCl2后，充分搅拌，在常温下反应1h，分离除杂后得到所述的硒化黄芪多糖。
其中，含硒试剂-SeOCl2中含硒6wt％。
其中，香菇多糖的制备方法为：将香菇依次进行干燥、粉碎、浸泡、水提得到香菇多糖粗提物，然后将香菇多糖粗提物依次用氯苯、氯化钙、草酸铵、胰蛋白酶、Sevage试剂进行除蛋白，然后醇沉，最后采用丙酮进行分级沉淀，得到所述香菇多糖。
其中，骨髓间质干细胞的制备方法为：将骨髓去除残留血液，剪碎，用胶原酶消化，然后再加入胰酶消化，消化液用筛网过滤，去除未消化组织，将过滤后的消化液用磷酸缓冲液稀释，离心，获得细胞，将细胞接种于培养基内进行培养，得到大量骨髓间充质干细胞。
最后应当说明的是，以上实施例仅用以说明本发明的技术方案，而非对本发明保护范围的限制，尽管参照较佳实施例对本发明作了详细地说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的实质和范围。
Claims (7)
1.一种含有骨髓间质干细胞的注射剂，其特征在于：所述的含有骨髓间质干细胞的注射剂主要由血清、林格氏液、葡萄糖、甘氨酸、硒化黄芪多糖、香菇多糖和骨髓间质干细胞混合而成。
2.根据权利要求1所述的一种含有骨髓间质干细胞的注射剂，其特征在于：每1L所述血清中含有以下组分：
林格氏液 30~50mL
葡萄糖 6~10g
甘氨酸 5~10g
硒化黄芪多糖 2~5g
香菇多糖 3~6g
骨髓间质干细胞 5~9g。
3.根据权利要求1或者2所述的一种含有骨髓间质干细胞的注射剂，其特征在于：所述的林格氏液为含有氯化钠、氯化钾和氯化钙的混合液，每100mL的所述林格氏液含有氯化钠850mg、氯化钠30mg、氯化钙33mg。
4.根据权利要求1或者2所述的一种含有骨髓间质干细胞的注射剂，其特征在于：所述的硒化黄芪多糖的制备方法为：取5~6kg的II型黄芪多糖加入到50~60mL的脱水吡啶中，用磁力搅拌器搅拌，搅拌10~15min，然后分三次滴入含硒试剂-SeOCl2，每次滴入1~3L的SeOCl2后，充分搅拌，在常温下反应1h，分离除杂后得到所述的硒化黄芪多糖。
5.根据权利要求4所述的一种含有骨髓间质干细胞的注射剂，其特征在于：所述的含硒试剂-SeOCl2中含硒5~6wt％。
6.根据权利要求1或者2所述的一种含有骨髓间质干细胞的注射剂，其特征在于：所述的香菇多糖的制备方法为：将香菇依次进行干燥、粉碎、浸泡、水提得到香菇多糖粗提物，然后将香菇多糖粗提物依次用氯苯、氯化钙、草酸铵、胰蛋白酶、Sevage试剂进行除蛋白，然后醇沉，最后采用丙酮进行分级沉淀，得到所述香菇多糖。
7.根据权利要求1或者2所述的一种含有骨髓间质干细胞的注射剂，其特征在于：所述的骨髓间质干细胞的制备方法为：将骨髓去除残留血液，剪碎，用胶原酶消化，然后再加入胰酶消化，消化液用筛网过滤，去除未消化组织，将过滤后的消化液用磷酸缓冲液稀释，离心，获得细胞，将细胞接种于培养基内进行培养，得到大量骨髓间充质干细胞。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910830407.XA CN110420223A (zh) | 2019-09-04 | 2019-09-04 | 一种含有骨髓间质干细胞的注射剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910830407.XA CN110420223A (zh) | 2019-09-04 | 2019-09-04 | 一种含有骨髓间质干细胞的注射剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110420223A true CN110420223A (zh) | 2019-11-08 |
Family
ID=68417314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910830407.XA Withdrawn CN110420223A (zh) | 2019-09-04 | 2019-09-04 | 一种含有骨髓间质干细胞的注射剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110420223A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113876703A (zh) * | 2021-11-06 | 2022-01-04 | 王啸远 | 一种骨髓间充质干细胞注射液及其制备方法和应用 |
| EP4185305A4 (en) * | 2020-09-09 | 2024-08-28 | Univ Duke | METHODS OF REPROGRAMMING TARGET CELLS |
-
2019
- 2019-09-04 CN CN201910830407.XA patent/CN110420223A/zh not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4185305A4 (en) * | 2020-09-09 | 2024-08-28 | Univ Duke | METHODS OF REPROGRAMMING TARGET CELLS |
| CN113876703A (zh) * | 2021-11-06 | 2022-01-04 | 王啸远 | 一种骨髓间充质干细胞注射液及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100813914B1 (ko) | 장내 생균제 공동-발효 배양물에 의한 천연 의약의 전환과변형 | |
| Lim et al. | Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases | |
| CN110420223A (zh) | 一种含有骨髓间质干细胞的注射剂 | |
| Furth et al. | Hormone-secreting transplantable neoplasms of the pituitary induced by I131. | |
| CN103405577B (zh) | 一种增强免疫力、缓解疲劳的药用组合物 | |
| CN112890064A (zh) | 一种复合胶原蛋白肽固体饮料及其制备方法 | |
| CN117959350B (zh) | 一种基于复合干细胞svf的骨关节炎治疗组合物 | |
| US9956317B2 (en) | Clinical applications of formulations containing adipose-derived stem cells | |
| CN113122497B (zh) | 工程化线粒体及其制备方法 | |
| CN102008474B (zh) | 氯化两面针碱在制备抗自身免疫病和抗移植排斥疾病药物中的应用 | |
| KR101659158B1 (ko) | 메트포민이 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
| CN110157761A (zh) | 蜂王幼虫中蛋白质酶解制备抗氧化肽的方法 | |
| CN1291725C (zh) | 用于治疗宫颈糜烂的红色诺卡氏菌细胞壁骨架制剂及其制法 | |
| Li et al. | Neuroprotective effect of bone marrow stromal cell combination with atorvastatin in rat model of spinal cord injury | |
| Tremolada et al. | Mesenchymal Stromal Cells and Micro Fragmented Adipose Tissue: New Horizons of Effectiveness of Lipogems. J | |
| Yub et al. | Immunomodulatory role of mesenchymal stem cells in liver transplantation: status and prospects | |
| CN101485685B (zh) | 骨髓间质干细胞在制备治疗系统性硬化症药物中的应用 | |
| CN114222814B (zh) | 具有比人外周血的自然杀伤细胞更高水平的自然细胞毒性受体、杀伤活性及γ-干扰素生产能力的记忆样自然杀伤细胞的制备方法 | |
| CN109294984B (zh) | 一种体内高效扩增nk细胞的香菇多糖胶囊及其制备方法 | |
| CN109432116A (zh) | 黄芪皂苷ⅲ在制备肿瘤免疫治疗药物中的用途 | |
| CN116617264B (zh) | 一种用于抗阿兹海默症的间充质干细胞制剂及其制备方法 | |
| CN118436767B (zh) | 基于脂肪干细胞svf的骨关节炎治疗组合物及其制备方法 | |
| CN103463128A (zh) | 哺乳动物骨髓细胞内液的制备方法及其用途 | |
| CN102631368B (zh) | 骨髓间质干细胞在制备治疗自身免疫性疾病药物中的应用 | |
| CA2437690A1 (en) | Ganoderma lucidum spores for treatment of autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191108 |